Eli Lilly Eyes Return to Trillion-Dollar Valuation Following FDA Approval of Oral GLP-1 Drug

Eli Lilly (NYSE: LLY) is positioning itself for a potential return to the trillion-dollar market cap club following the FDA's April 1 approval of Foundayo. The new oral GLP-1 weight loss medication offers a non-injectable alternative, potentially broadening the company's patient base by attracting those hesitant to use injectable treatments. The approval comes as Lilly continues to capitalize on the massive success of its existing GLP-1 portfolio, including Mounjaro and Zepbound. These treatments have fueled a quarterly growth rate exceeding 40% in recent periods, cementing the company's leadership in the obesity and diabetes sectors. Currently valued at approximately $830 billion, Eli Lilly requires a 20% increase in share price to reclaim its $1 trillion milestone. While the stock continues to trade at a premium—currently over 40 times trailing earnings—this represents a significant compression from the 70x multiple seen a year prior. Despite the regulatory win, the stock has not seen an immediate surge, as investors had largely priced in the approval based on strong clinical trial data. However, with a consensus analyst price target of $1,224, there remains a projected upside of roughly 32%, provided the company can maintain its growth trajectory amidst increasing competition in the GLP-1 space.